A phase I study of bizelesin, a highly potent and selective DNA-interactive agent, in patients with advanced solid malignancies

Annals of Oncology

Volumn 14, Issue 5, 2003, Pages 775-782

  Schwartz, G H ^a   Patnaik, A ^b   Hammond, L A ^b   Rizzo, J ^b   Berg, K ^b   Von Hoff, D D ^b   Rowinsky, E K ^b  

^a BROOKE ARMY MEDICAL CENTER   (United States)

^b CTRC Institute for Drug Development   (United States)

Author keywords

Bizelesin; Cyclopropylpyrroloindole; DNA active agent; Phase I study

Indexed keywords

ADENOSINE; ADOZELESIN; ANTINEOPLASTIC AGENT; BIZELESIN; CARBOPLATIN; CARZELESIN; CYTOTOXIC AGENT; DNA; DOCETAXEL; DOXORUBICIN; DRUG METABOLITE; GEMCITABINE; NAVELBINE; PACLITAXEL; THYMIDINE; TOPOTECAN; U 77809; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ANALYTIC METHOD; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW TOXICITY; CLINICAL TRIAL; COLONY FORMATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DNA DAMAGE; DNA SEQUENCE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DNA INTERACTION; DRUG MECHANISM; DRUG POTENCY; DRUG SELECTIVITY; DRUG SYNTHESIS; DRUG TOLERABILITY; FATIGUE; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; FEMALE; HEMATOLOGIC DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; NAUSEA; NEUTROPENIA; NONHUMAN; OVARY CARCINOMA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RELIABILITY; SENSITIVITY ANALYSIS; SOLID TUMOR; SPECIES DIFFERENCE; THROMBOCYTOPENIA;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, ALKYLATING; DNA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INDOLES; INTERCALATING AGENTS; MALE; MIDDLE AGED; NEOPLASMS; UREA;

EID: 0037767183     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdg215     Document Type: Article

References (29)

1. Hanka LJ, Dietz A, Gerpheide SA et al. CC-1065 (NSC 298223), a new antitumor antibiotic. Production, in vitro biologic activity, microbiological assays and taxonomy of the producing microorganism. J Antibiot 1978; 31: 1211-1217.
2. Douros J, Suffness M. New antitumor substances of natural origin. Cancer Treat Rev 1981; 8: 63-87.
3. Warpehoski MA, Gebhard I, Kelly RC et al. Stereoelectronic factors influencing the biological activity and DNA interaction of synthetic antitumor agents modeled on CC-1065. J Med Chem 1988; 31: 590-603.
4. Li LH, Swenson DH, Schpok SL et al. CC-1065 (NSC 298223), a novel antitumor agent that interacts strongly with double-stranded DNA. Cancer Res 1982; 42: 999-1004.
5. Chidester CG, Krueger WC, Mizsak SA et al. The structure of CC-1065, a potent antitumor agent, and its binding to DNA. J Am Chem Soc 1981; 103: 7629-7635.
6. Swenson DH, Li LH, Hurley LH et al. Mechanism of interaction of CC-1065 (NSC 298223) with DNA. Cancer Res 1982; 42: 2821-2828.
7. Reynolds VL, Molineux IJ, Kaplan DJ et al. Reaction of the antitumor antibiotic CC-1065 with DNA. Location of the site of thermally induced strand breakage and analysis of DNA sequence specificity. Biochemistry 1985; 24: 6228-6237.
8. Aristoff PA, McGovren JP. Antitumor agents based on CC-1065. DN&P 1993; 6: 229-234.
9. McGovren JP, Clarke GL, Pratt EA, DeKoning TF. Preliminary toxicity studies with the DNA-binding antibiotic, CC-1065. J Antibiot 1984; 37: 63-70.
10. Shamdas GJ, Alberts DS, Modiano M et al. Phase I study of adozelesin (U-73,975) in patients with solid tumors. Anticancer Drugs 1994; 5: 10-14.
11. Fleming GF, Ratain MJ, O'Brien SM et al. Phase I study of adozelesin administered by 24-hour continuous intravenous infusion. J Natl Cancer Inst 1994; 86: 368-372.
12. Foster BJ, LoRusso PM, Poplin E et al. Phase I trial of adozelesin using the treatment schedule of daily x5 every 3 weeks. Invest New Drugs 1996; 13: 321-326.
13. Burris HA, Dieras VC, Tunca M et al. Phase I study with the DNA sequence-specific agent adozelesin. Anticancer Drugs 1997; 8: 588-596.
14. Cristofanilli M, Bryan WJ, Miller LL et al. Phase II study of adozelesin in untreated metastatic breast cancer. Anticancer Drugs 1998; 9: 779-782.
15. Awada A, Punt CJ, Piccart MJ et al. Phase I study of carzelesin (U-80,244) given (4-weekly) by intravenous bolus schedule. Br J Cancer 1999; 79: 1454-1461.
16. Wolff I, Bench K, Beijnen JH et al. Phase I clinical and pharmacokinetic study of carzelesin (U-80244) given daily for five consecutive days. Clin Cancer Res 1996; 2: 1717-1723.
17. Pavlidis N, Aamdal S, Awada A et al. Carzelesin phase II study in advanced breast, ovarian, colorectal, gastric, head and neck cancer, non-Hodgkin's lymphoma and malignant melanoma: a study of the EORTC early clinical studies group (ECSG). Cancer Chemother Pharmacol 2000; 46: 167-171.
18. Lee CS, Gibson NW. DNA damage and differential cytotoxicity produced in human carcinoma cells by CC-1065 analogues, U-73,975 and U-77,779. Cancer Res 1991; 51: 6586-6591.
19. Hightower RD, Sevin BU, Perras J et al. In vitro evaluation of the novel chemotherapeutic agents U-73,975, U-77,779, and U-80,244 in gynecologic cancer cell lines. Cancer Invest 1993; 11: 276-282.
20. Walker DL, Reid JM, Ames MM. Preclinical pharmacology of bizelesin, a potent bifunctional analog of the DNA-binding antibiotic CC-1065. Cancer Chemother Pharmacol 1994; 34: 317-322.
21. Herzig MC, Rodriguez KA, Trevino AV et al. The genome factor in region-specific DNA damage: the DNA-reactive drug U-78779 prefers mixed A/T-G/C sequences at the nucleotide level but is region-specific for long pure AT islands at the genomic level. Biochemistry 2002; 41: 1545-1555.
22. Woynarowski JM, Trevino AV, Rodriguez KA et al. AT-rich islands in genomic DNA as a novel target for AT-specific DNA-reactive antitumor drugs. J Biol Chem 2001; 276: 40555-40566.
23. Woynarowski JM, Napier C, Trevino AV, Arnett B. Region-specific DNA damage by AT-specific DNA-reactive drugs is predicted by drug binding specificity. Biochemistry 2000; 39: 9917-9927.
24. Woynarowski JM, Chapman WG, Napier C, Herzig MC. Induction of AT-specific DNA-interstrand crosslinks by bizelesin in genomic and simian virus 40 DNA. Biochim Biophys Acta 1999; 1444: 201-217.
25. Woynarowski JM, Beerman TA. Effects of bizelesin (U-77,779), a bifunctional alkylating minor groove binder, on replication of genomic and simian virus 40 DNA in BSC-1 cells. Biochim Biophys Acta 1997; 1353: 50-60.
26. Woynarowski JM, McHugh MM, Gawron LS, Beerman TA. Effects of bizelesin (U-77779), a bifunctional alkylating minor groove agent, on genomic and simian virus 40 DNA. Biochemistry 1995; 34: 13042-13050.
27. Volpe DA, Tomaszewski JE, Parchment RE et al. Myelotoxic effects of the bifunctional alkylating agent bizelesin on human, canine and murine myeloid progenitor cells. Cancer Chemother Pharmacol 1996; 39: 143-149.
28. Pitot H, Reid JM, Sloan JA et al. A phase I study of bizelesin (NSC 615291) in patients with advanced solid tumors. Clin Cancer Res 2002; 8: 712-717.
29. Allen TM. Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer 2002; 2: 750-763.